Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 4/20 | 0.34 |
| ▸ | APP | P05067 | 3/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12234896 | 0.83 | HTR2B (0.38) | ALDH1A1GAAMAPTHSD17B10CYP19A1 | |
| SCHEMBL12234883 | 0.82 | AKR1B1 (0.41) | MAP3K14MAPTBACE1APP | |
| SCHEMBL5835328 | 0.77 | RARA (0.40) | MAP3K14ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL6124180 | 0.77 | ITGB2 (0.41) | MAP3K14GAA | |
| SCHEMBL19889240 | 0.77 | MAP3K14 (0.40) | MAP3K14ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL19889242 | 0.76 | MAP3K14 (0.39) | MAP3K14ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL29295492 | 0.75 | MAP3K14 (0.44) | MAP3K14ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL8089535 | 0.73 | MAP3K14 (0.47) | MAP3K14ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL12234870 | 0.72 | AKR1B1 (0.50) | MAPTBACE1APP | |
| SCHEMBL23996838 | 0.70 | MAP3K14 (0.33) | MAP3K14ALDH1A1GAAMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487099-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120107328-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2012-05-03 | — | — | US | disclosed |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107328-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MAP3K14 3819/4885ALDH1A1 1705/4885GAA 11/4885 |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MAP3K14 3091/4885ALDH1A1 3991/4885GAA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.